Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 35

Sort by

Sort Order Select

Journal Articles

Safety and efficacy of elranatamab + nirogacestat in patients with relapsed or refractory multiple myeloma: Results from the Phase 1b MagnetisMM-4 study

Ola Landgren, Suzanne Trudel, Jacalyn Rosenblatt, Arleigh McCurdy, Sumit Madan, Syed Abbas Ali, Nizar Bahlis, Eli Gabayan, Robert Vescio, Melissa O'Gorman, Shinta Cheng, Sibo Jiang, Margaret Hoyle, Jay Cheng, Erik Vandendries, Noopur Raje

Blood (2025) 146 (Supplement 1): 4058.

https://doi.org/10.1182/blood-2025-4058

Published: 2025

Journal Articles

Real-world analysis of thromboprophylaxis use during autologous hematopoietic stem cell transplantation for lymphoma and multiple myeloma

Hannah Lee, Haein Kim, Brittany McGalliard, Eyman Sonbol, David Oveisi, Justin Darrah, Robert Vescio, Noah Merin, Akil Merchant, Joshua Sasine, John Chute, Oksana Volod, Ronald Paquette

Blood (2025) 146 (Supplement 1): 3124.

https://doi.org/10.1182/blood-2025-3124

Published: 2025

Journal Articles

Fludarabine and total body irradiation 800 cgy or 1125 cgy for allogeneic stem cell transplant using graft versus host disease prophylaxis with post-transplant cyclophosphamide and tacrolimus, without mycophenolate mofetil (OmitMMF trial)

Ronald Paquette, Haein Kim, Noah Merin, John Chute, Justin Darrah, Hannah Lee, David Oveisi, Joshua Sasine, Robert Vescio, Vinicius Calsavara, Joseph Lownik, Akil Merchant

Blood (2025) 146 (Supplement 1): 4244.

https://doi.org/10.1182/blood-2025-4244

Published: 2025

Journal Articles

Aiming at immune fitness in cancer: Longitudinal functional profiling to predict clinical outcome

Blood (2025) 146 (Supplement 1): 4785.

https://doi.org/10.1182/blood-2025-4785

Published: 2025

Journal Articles

Ruxolitinib and Methylprednisolone for Treatment of Patients with Relapsed/Refractory Multiple Myeloma

James R. Berenson, Daisy Martinez, Tahmineh Safaie, Ralph Boccia, Honghao H Yang, Mehdi M. Moezi, Stephen Lim, Gary Edward Schwartz, Shahrooz Eshaghian, Regina Swift, Benjamin Eades, Sean Elliott Bujarski, Bernard Sean Regidor, Clara Kim, Susanna Kim, Robert Vescio

Blood (2022) 140 (Supplement 1): 12610–12611.

https://doi.org/10.1182/blood-2022-163872

Published: 2022

Journal Articles

Efficacy and Safety of Ruxolitinib and Steroids for Treating Patients with Relapsed or Refractory Multiple Myeloma

James R. Berenson, Daisy Martinez, Tahmineh Safaie, Noemi Silagan, Jennifer To, Tanya M. Spektor, Eli Forouzan, Regina Swift, Benjamin Eades, Shahrooz Eshaghian, Gary Schwartz, Ralph V. Boccia, Honghao H Yang, Mehdi M. Moezi, Stephen Lim, Robert Vescio

Blood (2021) 138 (Supplement 1): 2727.

https://doi.org/10.1182/blood-2021-151016

Published: 2021

Journal Articles

Retrospective Analysis of Response Rates to Anti-CD38 Monoclonal Antibody Containing Regimens Among Multiple Myeloma Patients with Prior Exposure to Daratumumab or Isatuximab

David Yashar, Bernard Sean S. Regidor, Scott Kristian Jew, Sean Bujarski, Marissa-Skye Goldwater, Regina Swift, Gary Edward Schwartz, Shahrooz Eshaghian, Robert Vescio, James R. Berenson

Blood (2021) 138 (Supplement 1): 3785.

https://doi.org/10.1182/blood-2021-154350

Published: 2021

Journal Articles

Efficacy and Safety of Ruxolitinib and Steroids for Treating Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

James R. Berenson, MD, Noemi Silagan, MD, Jennifer To, BS, Tanya M. Spektor, PhD, Daisy Martinez, Armando J. Sanchez, Eli Forouzan, Regina Swift, Benjamin Eades, PharmD, Gary Schwartz, MD, Shahrooz Eshaghian, MD, Ralph V. Boccia, MD, Honghao Hank Yang, Stephen Lim, MD, Robert Vescio, MD

Blood (2020) 136 (Supplement 1): 36.

https://doi.org/10.1182/blood-2020-143005

Published: 2020

Journal Articles

Optimizing Care: Discontinuing Medications Prior to Daratumumab and Hyaluronidase-Fihj Subcutaneous Injection (OMIT)

Anya Yudchyts, PharmD, Tiffany Lin, PharmD, Robert Vescio, MD

Blood (2020) 136 (Supplement 1): 22–23.

https://doi.org/10.1182/blood-2020-141644

Published: 2020

Journal Articles

A Phase 1 Trial of Ruxolitinib, Lenalidomide and Methylprednisolone for Patients with Relapsed/Refractory Multiple Myeloma (MM)

James R. Berenson, MD, Jennifer To, BS, Tanya M. Spektor, PhD, Daisy Martinez, Armando J. Sanchez, MBA, Carley Turner, CCRP, Regina Swift, Benjamin Eades, PharmD, Gary Schwartz, MD, Shahrooz Eshaghian, MD, Laura V. Stampleman, Robert A. Moss, MD, Youram Nassir, MD, Ravindranath Patel, MD, Alberto Bessudo, MD, Daniel Greenwald, MD, Ralph V. Boccia, MD, Stephen Lim, MD, Robert Vescio, MD

Blood (2019) 134 (Supplement_1): 1903.

https://doi.org/10.1182/blood-2019-131370

Published: 2019

Journal Articles

A Phase 1 Trial of Ruxolitinib, Lenalidomide and Methylprednisolone for Relapsed/Refractory Multiple Myeloma Patients

James R Berenson, MD, To Jennifer, BS, Tanya M. Spektor, PhD, Carley Turner, CCRP, Regina Swift, Benjamin Eades, PharmD, Gary Schwartz, MD, Shahrooz Eshaghian, MD, Laura V. Stampleman, Robert A. Moss, MD, Alberto Bessudo, MD, Ravindranath Patel, MD, Stephen Lim, MD, Robert Vescio, MD

Blood (2018) 132 (Supplement 1): 1988.

https://doi.org/10.1182/blood-2018-99-119274

Published: 2018

Journal Articles

Efficacy and Safety of Pomalidomide As a Replacement Therapy for Lenalidomide for Relapsed/Refractory Multiple Myeloma Patients Refractory to a Lenalidomide-Containing Combination Regimen

James R Berenson, MD, Alexa Cohen, Tanya M. Spektor, PhD, Ashkan Lashkari, MD, Roy Mackintosh, MD, Alberto Bessudo, MD, Haresh Jhangiani, Nashat Gabrail, MD, Ibrahim Nakhoul, MD, Samir Kubba, MD, Jeffrey D. Neidhart, MD BS, Maluso Tina, Regina Swift, Robert Vescio, MD

Blood (2017) 130 (Supplement 1): 3106.

https://doi.org/10.1182/blood.V130.Suppl_1.3106.3106

Published: 2017

Journal Articles

a Phase 1/2 Trial of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

James Berenson, MD, Laura Stampleman, MD, Alberto Bessudo, MD, Peter J Rosen, MD, Leonard M. Klein, MD, Thomas Woliver, MD, Marshall S. Flam, MD, Shahrooz Eshaghian, MD, Youram Nassir, MD, Swift A Regina, RN, Wang James, Eades Benjamin, PharmD, Tanya M. Spektor, PhD, Robert Vescio, MD

Blood (2015) 126 (23): 5383.

https://doi.org/10.1182/blood.V126.23.5383.5383

Published: 2015

Journal Articles

A Phase 1/2 Trial of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed/Refractory Multiple Myeloma

James R. Berenson, MD, Laura V. Stampleman, MD, Alberto Bessudo, MD, Peter J. Rosen, MD, Leonard M Klein, MD, Thomas Woliver, MD, Marshall S. Flam, MD, Shahrooz Eshaghian, MD, Youram Nassir, MD, Regina A. Swift, RN, Robert Vescio, MD

Blood (2014) 124 (21): 4774.

https://doi.org/10.1182/blood.V124.21.4774.4774

Published: 2014

Journal Articles

A Multi-Center Phase 1b, Open-Label, Dose-Finding Pilot Study to Evaluate the Combination of Carfilzomib and Cyclophosphamide with Dexamethasone (CCyD) Prior to Autologous Stem Cell Transplant (ASCT) in Patients with Transplant Eligible Newly Diagnosed Multiple Myeloma

William I. Bensinger, MD, Robert Vescio, MD, Cristina Gasparetto, MD, Elber S. Camacho, MD, Rajneesh Nath, MD, Christina L. Gomes, MD, David D. Smith, PhD, Jatin J. Shah, Brian G. M. Durie, MD

Blood (2014) 124 (21): 4739.

https://doi.org/10.1182/blood.V124.21.4739.4739

Published: 2014

Journal Articles

Long-Term Ixazomib Maintenance Is Tolerable and Improves Depth of Response Following Ixazomib-Lenalidomide-Dexamethasone Induction in Patients (Pts) with Previously Untreated Multiple Myeloma (MM): Phase 2 Study Results

Shaji Kumar, MD, Jesus G. Berdeja, MD, Ruben Niesvizky, MD, Sagar Lonial, MD, Jacob P. Laubach, MD, Mehdi Hamadani, MD, A. Keith Stewart, MD, Parameswaran N. Hari, MD, Vivek Roy, MD, Robert Vescio, MD, Jonathan L. Kaufman, MD, Deborah Berg, RN, MSN, Eileen Liao, PhD, Ai-Min Hui, MD PhD, S. Vincent Rajkumar, MD, Paul G. Richardson

Blood (2014) 124 (21): 82.

https://doi.org/10.1182/blood.V124.21.82.82

Published: 2014

Journal Articles

Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin For Patients With Relapsed/Refractory Multiple Myeloma: Results From a Phase 1/2 Trial

James R. Berenson, MD, James D. Hilger, Ph.D., Leonard Klein, MD, Alberto Bessudo, MD, Peter J. Rosen, MD, Shahrooz Eshaghian, MD, Youram Nassir, MD, Regina A. Swift, RN, Robert Vescio, MD

Blood (2013) 122 (21): 3218.

https://doi.org/10.1182/blood.V122.21.3218.3218

Published: 2013

Journal Articles

Bone Marker-Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Multiple Myeloma: Final Results of the Z-MARK Study

Noopur Raje, Robert Vescio, MD, Charles W. Montgomery, MD, Joseph T Hadala, MS, Ghulam Warsi, PhD, Solveig G. Ericson, MD, PhD, Kenneth C. Anderson, MD

Blood (2012) 120 (21): 4077.

https://doi.org/10.1182/blood.V120.21.4077.4077

Published: 2012

Journal Articles

A Phase 1/2 Study of Weekly MLN9708, an Investigational Oral Proteasome Inhibitor, in Combination with Lenalidomide and Dexamethasone in Patients with Previously Untreated Multiple Myeloma (MM)

Shaji K. Kumar, MD, Jesus G. Berdeja, MD, Ruben Niesvizky, MD, Sagar Lonial, MD, Mehdi Hamadani, MD, A. Keith Stewart, MBA, MB, CHB, Vivek Roy, M.D., Parameswaran Hari, MBBS, MD, MRCP, Robert Vescio, MD, Deborah Berg, RN, MSN, Jianchang Lin, Alessandra Di Bacco, PhD, Neeraj Gupta, PhD, Ai-Min Hui, MD, Paul G. Richardson, MD

Blood (2012) 120 (21): 332.

https://doi.org/10.1182/blood.V120.21.332.332

Published: 2012

Journal Articles

A Phase 1/2 Study of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed/Refractory Multiple Myeloma.

James R. Berenson, MD, James D. Hilger, Ph.D., Leonard M. Klein, MD, Shahrooz Eshaghian, MD, Youram Nassir, MD, Regina A. Swift, RN, Robert Vescio, MD

Blood (2012) 120 (21): 2979.

https://doi.org/10.1182/blood.V120.21.2979.2979

Published: 2012

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Safety and efficacy of elranatamab + nirogacestat in patients with relapsed or refractory multiple myeloma: Results from the Phase 1b MagnetisMM-4 study

Real-world analysis of thromboprophylaxis use during autologous hematopoietic stem cell transplantation for lymphoma and multiple myeloma

Fludarabine and total body irradiation 800 cgy or 1125 cgy for allogeneic stem cell transplant using graft versus host disease prophylaxis with post-transplant cyclophosphamide and tacrolimus, without mycophenolate mofetil (OmitMMF trial)

Aiming at immune fitness in cancer: Longitudinal functional profiling to predict clinical outcome

Ruxolitinib and Methylprednisolone for Treatment of Patients with Relapsed/Refractory Multiple Myeloma

Efficacy and Safety of Ruxolitinib and Steroids for Treating Patients with Relapsed or Refractory Multiple Myeloma

Retrospective Analysis of Response Rates to Anti-CD38 Monoclonal Antibody Containing Regimens Among Multiple Myeloma Patients with Prior Exposure to Daratumumab or Isatuximab

Efficacy and Safety of Ruxolitinib and Steroids for Treating Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Optimizing Care: Discontinuing Medications Prior to Daratumumab and Hyaluronidase-Fihj Subcutaneous Injection (OMIT)

A Phase 1 Trial of Ruxolitinib, Lenalidomide and Methylprednisolone for Patients with Relapsed/Refractory Multiple Myeloma (MM)

A Phase 1 Trial of Ruxolitinib, Lenalidomide and Methylprednisolone for Relapsed/Refractory Multiple Myeloma Patients

Efficacy and Safety of Pomalidomide As a Replacement Therapy for Lenalidomide for Relapsed/Refractory Multiple Myeloma Patients Refractory to a Lenalidomide-Containing Combination Regimen

a Phase 1/2 Trial of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

A Phase 1/2 Trial of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed/Refractory Multiple Myeloma

A Multi-Center Phase 1b, Open-Label, Dose-Finding Pilot Study to Evaluate the Combination of Carfilzomib and Cyclophosphamide with Dexamethasone (CCyD) Prior to Autologous Stem Cell Transplant (ASCT) in Patients with Transplant Eligible Newly Diagnosed Multiple Myeloma

Long-Term Ixazomib Maintenance Is Tolerable and Improves Depth of Response Following Ixazomib-Lenalidomide-Dexamethasone Induction in Patients (Pts) with Previously Untreated Multiple Myeloma (MM): Phase 2 Study Results

Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin For Patients With Relapsed/Refractory Multiple Myeloma: Results From a Phase 1/2 Trial

Bone Marker-Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Multiple Myeloma: Final Results of the Z-MARK Study

A Phase 1/2 Study of Weekly MLN9708, an Investigational Oral Proteasome Inhibitor, in Combination with Lenalidomide and Dexamethasone in Patients with Previously Untreated Multiple Myeloma (MM)

A Phase 1/2 Study of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed/Refractory Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only